共 45 条
- [21] Lack of lipid raft domain reorganization following ligation of CD20 is associated with resistance to rituximab-induced complement-dependent cytotoxicityBLOOD, 2005, 106 (11) : 284B - 284BOlejniczak, SHHernandez-Ilizaliturri, FJClements, JLCzuczman, MS
- [22] Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levelsCLINICAL CANCER RESEARCH, 2008, 14 (05) : 1561 - 1570Czuczman, Myron S.Olejniczak, ScottGowda, ArunaKotowski, AdamBinder, ArvinderKaur, HarmanKnight, JoyStarostik, PetrDeans, JulieHernandez-Ilizaliturri, Francisco J.
- [23] Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasmsImmunologic Research, 2010, 46 : 192 - 205Wasif RiazFrancisco J. Hernandez-IlizaliturriMyron S. Czuczman
- [24] Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasmsIMMUNOLOGIC RESEARCH, 2010, 46 (1-3) : 192 - 205Riaz, WasifHernandez-Ilizaliturri, Francisco J.Czuczman, Myron S.
- [25] Lenalidomide.(Revlimid®) enhances monoclonal antibody-associated anti-tumor activity against rituximab-sensitive and rituximab-resistant B-cell lymphoma cell lines.BLOOD, 2006, 108 (11) : 714A - 714AReddy, NishithaCruz, RaymondHernandez-Ilizaliturri, FranciscoKnight, JoyCzuczman, Myron S.
- [26] Differential Patterns of Gene Expression and CD20 Localisation by the Type II Anti-CD20 Antibody Obinutuzumab (GA101) Compared with the Type I Antibody Rituximab Suggests Binding to Functionally Distinct CD20 Subpopulations on B-Cell Lymphoma Cell LinesBLOOD, 2011, 118 (21) : 1589 - 1590Niederfellner, GerhardMundigl, OlafLifke, AlexanderFranke, AndreasBaer, UteBurtscher, HelmutMaisel, DanielaBelousov, AntonWeidner, K. MichaelUmana, PabloKlein, Christian
- [27] The emergence of CD20−/CD19− tumor cells after rituximab therapy for Epstein–Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosisEuropean Journal of Pediatrics, 2014, 173 : 1615 - 1618Nobuyuki YamamotoNoriyuki NishimuraMai TakeuchiTomoo ItoHiroshi YokozakiSatoshi HiraseIkuko KubokawaTakeshi MoriTomoko YanaiAkira HayakawaYasuhiro TakeshimaHisahide NishioMasafumi MatsuoKen-Ichi ImadomeKazumoto Iijima
- [28] Impaired Ca++ mobilization in rituximab-resistant cells (RRCL) is associated with changes in the structure of CD20 antigen, down-regulation of Bax/Bak pro-apoptotic proteins and up-regulation of the endoplasmic reticulum (ER) Ca plus plus pump protein SERCA-3.JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 104S - 104SHernandez-Ilizaliturri, F. J.Kaur, H.Bhinder, A.Olejniczak, S.Knight, J.Czuczman, M. S.
- [29] Fibroblast Growth Factor Receptor 3 (FGFR3) Associated with the CD20 Antigen Regulates the Rituximab-induced Proliferation Inhibition in B-cell Lymphoma CellsJOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (44) : 37109 - 37118Kotani, NorihiroIshiura, YoshihitoYamashita, RyusukeOhnishi, TomokoHonke, Koichi
- [30] Obinutuzumab (GA101): A novel type II glycoengineered CD20 antibody exhibits enhanced cell death against Rituximab-resistant and -sensitive cell lines in B-cell non-Hodgkin lymphomaCANCER RESEARCH, 2012, 72Tiwari, Aradhana AwasthiAyello, JanetVan de Ven, CarmellaCairo, Mitchell S.